AU2009279865B2 - Anti-hepcidin-25 selective antibodies and uses thereof - Google Patents
Anti-hepcidin-25 selective antibodies and uses thereof Download PDFInfo
- Publication number
- AU2009279865B2 AU2009279865B2 AU2009279865A AU2009279865A AU2009279865B2 AU 2009279865 B2 AU2009279865 B2 AU 2009279865B2 AU 2009279865 A AU2009279865 A AU 2009279865A AU 2009279865 A AU2009279865 A AU 2009279865A AU 2009279865 B2 AU2009279865 B2 AU 2009279865B2
- Authority
- AU
- Australia
- Prior art keywords
- antibody
- hepcidin
- seq
- human
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/26—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Genetics & Genomics (AREA)
- General Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US8655708P | 2008-08-06 | 2008-08-06 | |
| US61/086,557 | 2008-08-06 | ||
| PCT/US2009/052044 WO2010017070A1 (en) | 2008-08-06 | 2009-07-29 | Anti-hepcidin-25 selective antibodies and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2009279865A1 AU2009279865A1 (en) | 2010-02-11 |
| AU2009279865B2 true AU2009279865B2 (en) | 2013-10-10 |
Family
ID=41165490
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2009279865A Ceased AU2009279865B2 (en) | 2008-08-06 | 2009-07-29 | Anti-hepcidin-25 selective antibodies and uses thereof |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US8609817B2 (https=) |
| EP (1) | EP2328931B1 (https=) |
| JP (1) | JP5730200B2 (https=) |
| KR (1) | KR101462307B1 (https=) |
| CN (1) | CN102112489B (https=) |
| AU (1) | AU2009279865B2 (https=) |
| BR (1) | BRPI0916624A2 (https=) |
| CA (1) | CA2733497C (https=) |
| DK (1) | DK2328931T3 (https=) |
| EA (1) | EA201170312A1 (https=) |
| ES (1) | ES2432018T3 (https=) |
| IL (1) | IL210643A (https=) |
| MX (1) | MX2011001363A (https=) |
| NZ (1) | NZ590863A (https=) |
| PL (1) | PL2328931T3 (https=) |
| PT (1) | PT2328931E (https=) |
| UA (1) | UA103032C2 (https=) |
| WO (1) | WO2010017070A1 (https=) |
| ZA (1) | ZA201100261B (https=) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1608683B1 (en) * | 2003-04-01 | 2011-11-23 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Antibodies directed against hepatitis c virus e1e2 complex and pharmaceutical compositions |
| PE20091261A1 (es) * | 2007-11-02 | 2009-08-17 | Lilly Co Eli | Anticuerpos anti-hepcidina |
| NZ606584A (en) | 2010-08-16 | 2014-10-31 | Pieris Ag | Binding proteins for hepcidin |
| AU2012350654C1 (en) | 2011-12-12 | 2018-05-10 | Pieris Ag | Methods for preventing or treating disorders by increasing bioavailability of iron and related pharmaceutical formulation |
| US10316103B1 (en) | 2012-03-30 | 2019-06-11 | Biocare Medical, Llc | Systems and methods for anti-Uroplakin III antibodies |
| US20140120560A1 (en) * | 2012-10-26 | 2014-05-01 | Claresa Levetan | Generation of new pancreatic beta cells |
| US10429390B2 (en) | 2012-12-18 | 2019-10-01 | Biocare Medical, Llc | Antibody cocktail systems and methods for classification of histologic subtypes in lung cancer |
| US9657098B2 (en) * | 2013-03-15 | 2017-05-23 | Intrinsic Lifesciences, Llc | Anti-hepcidin antibodies and uses thereof |
| WO2015051320A2 (en) * | 2013-10-03 | 2015-04-09 | Biocare Medical, Llc | Anti-sox10 antibody systems and methods |
| WO2016027469A1 (ja) * | 2014-08-21 | 2016-02-25 | 国立大学法人旭川医科大学 | ヘプシジンのスプライシングバリアント並びに該バリアントを指標とした癌の診断方法 |
| AU2015321462B2 (en) * | 2014-09-22 | 2020-04-30 | Intrinsic Lifesciences Llc | Humanized anti-hepcidin antibodies and uses thereof |
| EP3268027B1 (en) | 2015-03-13 | 2022-11-02 | Institut National de la Santé et de la Recherche Médicale (INSERM) | Hepcidin antagonists for use in the treatment of inflammation |
| CA3038894A1 (en) * | 2016-09-28 | 2018-04-05 | Board Of Regents, The University Of Texas System | Antibody and protein therapeutic formulations and uses thereof |
| EP3559039A1 (en) | 2016-12-22 | 2019-10-30 | Università Degli Studi Magna Graecia Catanzaro | A monoclonal antibody targeting a unique sialoglycosilated cancer-associated epitope of cd43 |
| WO2018234538A1 (en) | 2017-06-23 | 2018-12-27 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Hepcidin antagonist or agonist for use in the treatment of dysregulation of mo and/or mn metabolism |
| CN109948371B (zh) * | 2019-03-07 | 2021-06-25 | 深圳市智税链科技有限公司 | 为区块链节点发放身份证书的方法及相关装置 |
| CN114761013A (zh) | 2019-09-27 | 2022-07-15 | 迪斯克医药公司 | 治疗骨髓纤维化和相关病症的方法 |
| US12508262B2 (en) | 2020-04-30 | 2025-12-30 | Keros Therapeutics, Inc. | Methods of using ALK2 inhibitors |
| WO2021231798A1 (en) | 2020-05-13 | 2021-11-18 | Disc Medicine, Inc. | Anti-hemojuvelin (hjv) antibodies for treating myelofibrosis |
| WO2022098812A1 (en) | 2020-11-04 | 2022-05-12 | Keros Therapeutics, Inc. | Methods of treating iron overload |
| EP4279924A4 (en) * | 2021-01-18 | 2024-06-26 | FUJIFILM Corporation | ADSORPTION INHIBITOR FOR HEPCIDIN, ADSORPTION INHIBITOR METHOD, REFERENCE STANDARD, REAGENT, KIT AND MEASUREMENT METHODS |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060019339A1 (en) * | 2004-04-28 | 2006-01-26 | Xavier Lauth | Measurement of bioactive hepcidins |
| US20070224186A1 (en) * | 2002-11-19 | 2007-09-27 | Hasan Kulaksiz | Diagnostic methods for diseases by screening for hepcidin in human or animal tissues, blood or body fluids; monoclonal antibodies specific to human hepcidin and associated uses therefor |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE478145T1 (de) | 1999-06-02 | 2010-09-15 | Genentech Inc | Sekretierte und transmembran polypeptide und dafür kodierende nukleinsäuren |
| US6262247B1 (en) | 1999-08-30 | 2001-07-17 | Incyte Genomics, Inc. | Polycyclic aromatic hydrocarbon induced molecules |
| JP4944360B2 (ja) | 2001-05-25 | 2012-05-30 | アンスティテュ ナシオナル ド ラ サント エ ド ラ ルシュルシェ メディカル(アンセルム) | 鉄ホメオスタシスの障害を治療するための医薬品を製造するためのヘプシジンの使用 |
| CN1173737C (zh) | 2002-10-21 | 2004-11-03 | 钱忠明 | Hepcidin(海魄喜定)在制药中的应用 |
| US7411048B2 (en) | 2002-11-19 | 2008-08-12 | Drg International, Inc. | Diagnostic method for diseases by screening for hepcidin in human or animal tissues, blood or body fluids |
| CA2506668C (en) | 2002-11-19 | 2014-08-19 | Drg International, Inc. | Diagnostic method for diseases by screening for hepcidin in human or animal tissues, blood or body fluids and therapeutic uses therefor |
| EP1644416A4 (en) | 2003-06-30 | 2007-08-29 | Centocor Inc | ANTI-TARGET AND GENETICALLY MODIFIED IMMUNOGLOBULIN-DERIVED PROTEINS, COMPOSITIONS, METHODS AND USES |
| JP2007518062A (ja) | 2003-09-29 | 2007-07-05 | バイオサイト インコーポレイテッド | 敗血症を診断する方法および診断するための組成物 |
| AU2003271174A1 (en) * | 2003-10-10 | 2005-04-27 | Chugai Seiyaku Kabushiki Kaisha | Double specific antibodies substituting for functional protein |
| AU2006223374B2 (en) * | 2005-03-11 | 2011-07-21 | Aspira Women’s Health Inc. | Biomarkers for ovarian cancer and endometrial cancer: hepcidin |
| TW201307390A (zh) * | 2007-02-02 | 2013-02-16 | Amgen Inc | 海帕西啶(hepcidin)、海帕西啶拮抗劑及使用方法 |
| GR1006896B (el) * | 2007-08-24 | 2010-07-20 | Ελληνικο Ινστιτουτο Παστερ, | Μεθοδος παραγωγης μιας πεπτιδικης ορμονης |
| WO2009044284A1 (en) | 2007-10-02 | 2009-04-09 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Antibodies specific for human hepcidin |
| PE20091261A1 (es) * | 2007-11-02 | 2009-08-17 | Lilly Co Eli | Anticuerpos anti-hepcidina |
| CA2722600C (en) | 2008-05-01 | 2014-01-21 | Amgen Inc. | Anti-hepcidin antibodies and methods of use |
-
2009
- 2009-07-29 EA EA201170312A patent/EA201170312A1/ru unknown
- 2009-07-29 UA UAA201101111A patent/UA103032C2/uk unknown
- 2009-07-29 PL PL09790908T patent/PL2328931T3/pl unknown
- 2009-07-29 DK DK09790908.9T patent/DK2328931T3/da active
- 2009-07-29 AU AU2009279865A patent/AU2009279865B2/en not_active Ceased
- 2009-07-29 WO PCT/US2009/052044 patent/WO2010017070A1/en not_active Ceased
- 2009-07-29 PT PT97909089T patent/PT2328931E/pt unknown
- 2009-07-29 MX MX2011001363A patent/MX2011001363A/es active IP Right Grant
- 2009-07-29 EP EP09790908.9A patent/EP2328931B1/en active Active
- 2009-07-29 JP JP2011522119A patent/JP5730200B2/ja not_active Expired - Fee Related
- 2009-07-29 CA CA2733497A patent/CA2733497C/en active Active
- 2009-07-29 KR KR1020117002748A patent/KR101462307B1/ko not_active Expired - Fee Related
- 2009-07-29 ES ES09790908T patent/ES2432018T3/es active Active
- 2009-07-29 CN CN200980129864.0A patent/CN102112489B/zh not_active Expired - Fee Related
- 2009-07-29 NZ NZ590863A patent/NZ590863A/xx not_active IP Right Cessation
- 2009-07-29 BR BRPI0916624A patent/BRPI0916624A2/pt not_active IP Right Cessation
- 2009-07-29 US US13/055,201 patent/US8609817B2/en not_active Expired - Fee Related
-
2011
- 2011-01-10 ZA ZA2011/00261A patent/ZA201100261B/en unknown
- 2011-01-13 IL IL210643A patent/IL210643A/en not_active IP Right Cessation
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070224186A1 (en) * | 2002-11-19 | 2007-09-27 | Hasan Kulaksiz | Diagnostic methods for diseases by screening for hepcidin in human or animal tissues, blood or body fluids; monoclonal antibodies specific to human hepcidin and associated uses therefor |
| US20060019339A1 (en) * | 2004-04-28 | 2006-01-26 | Xavier Lauth | Measurement of bioactive hepcidins |
Also Published As
| Publication number | Publication date |
|---|---|
| JP5730200B2 (ja) | 2015-06-03 |
| AU2009279865A1 (en) | 2010-02-11 |
| ZA201100261B (en) | 2012-06-27 |
| MX2011001363A (es) | 2011-04-26 |
| EP2328931A1 (en) | 2011-06-08 |
| IL210643A0 (en) | 2011-03-31 |
| KR20110031963A (ko) | 2011-03-29 |
| IL210643A (en) | 2015-09-24 |
| HK1156326A1 (en) | 2012-06-08 |
| DK2328931T3 (da) | 2013-09-30 |
| CN102112489B (zh) | 2014-05-14 |
| BRPI0916624A2 (pt) | 2015-12-01 |
| KR101462307B1 (ko) | 2014-11-17 |
| PT2328931E (pt) | 2013-11-07 |
| WO2010017070A1 (en) | 2010-02-11 |
| PL2328931T3 (pl) | 2014-01-31 |
| JP2011530514A (ja) | 2011-12-22 |
| UA103032C2 (uk) | 2013-09-10 |
| US20110189190A1 (en) | 2011-08-04 |
| CA2733497C (en) | 2015-06-02 |
| NZ590863A (en) | 2012-10-26 |
| CA2733497A1 (en) | 2010-02-11 |
| CN102112489A (zh) | 2011-06-29 |
| EA201170312A1 (ru) | 2012-03-30 |
| ES2432018T3 (es) | 2013-11-29 |
| EP2328931B1 (en) | 2013-08-14 |
| US8609817B2 (en) | 2013-12-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2009279865B2 (en) | Anti-hepcidin-25 selective antibodies and uses thereof | |
| TWI409276B (zh) | 抗-海帕西啶(hepcidin)抗體及其用途 | |
| AU2020245031A1 (en) | Antibodies to pyroglutamate amyloid-β and uses thereof | |
| CN110464842B (zh) | 包含抗pcsk9抗体的制剂及其用途 | |
| JP6027744B2 (ja) | ヒトインスリン測定方法及び測定試薬 | |
| US12459997B2 (en) | Compounds and methods targeting interleukin-19 | |
| US20150355199A1 (en) | Agents, kits and methods for complement factor h-related protein 1 detection | |
| EP2347004B1 (en) | Reagents and methods for detecting the polymorphic protein haptoglobin | |
| KR102421918B1 (ko) | 호산구 유래 신경독과 특이적으로 결합하는 단일클론항체 및 이의 용도 | |
| HK1156326B (en) | Anti-hepcidin-25 selective antibodies and uses thereof | |
| US12590977B2 (en) | Anti-ceruloplasmin antibodies and uses thereof | |
| KR102929013B1 (ko) | 대칭성 디메틸아르기닌에 특이적으로 결합하는 항체 및 이의 용도 | |
| WO2026084964A1 (en) | Anti-thyroid peroxidase antibodies and immunoassays | |
| CA3188429A1 (en) | Compounds and methods targeting human and mouse insl5 | |
| HK1142341B (en) | Anti-hepcidin antibodies and uses thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) | ||
| MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |